PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15299075-0	2004	Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.	Auristatin E	38-50	transmembrane protein with EGF like and two follistatin like domains 2	Homo sapiens	31-37	
15299075-5	2004	To evaluate anti-TMEFF2 mAbs as potential ADCs, one mAb was conjugated to the cytotoxic agent auristatin E via a cathepsin B-sensitive valine-citrulline linker.	Auristatin E	94-106	transmembrane protein with EGF like and two follistatin like domains 2	Homo sapiens	17-23	
15299075-5	2004	To evaluate anti-TMEFF2 mAbs as potential ADCs, one mAb was conjugated to the cytotoxic agent auristatin E via a cathepsin B-sensitive valine-citrulline linker.	Auristatin E	94-106	cathepsin B	Homo sapiens	113-124	
15299075-5	2004	To evaluate anti-TMEFF2 mAbs as potential ADCs, one mAb was conjugated to the cytotoxic agent auristatin E via a cathepsin B-sensitive valine-citrulline linker.	valine-citrulline	135-152	cathepsin B	Homo sapiens	113-124